Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KRRO - Korro Bio, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.57
DETAILS
HIGH:
$30.00
LOW:
$10.00
MEDIAN:
$22.00
CONSENSUS:
$19.57
UPSIDE:
32.95%
Stock News
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Korro to Present at the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D.
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATD Demonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATD Pre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development.
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing for KRRO-121 expected in the second half of 2026 Advanced early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD); on track to announce development candidate in second quarter of 2026 Executed oversubscribed $85 million private placement to support the achievement of value inflection points for multiple RNA editing clinical programs and extend cash runway into the second half of 2028 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the first quarter ended March 31, 2026, and provided a corporate update.
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Chief Executive Officer and President, Jeffrey Cerio, SVP and General Counsel, Todd Chappell, Chief Operating Officer, and Loïc Vincent, Chief Scientific Officer, will participate in the following investor conferences: HCW 4th Annual BioConnect Nasdaq Investor Conference Format: Fireside chat moderated by Mitchell Kapoor, Director and Senior Analyst, Biotechnology Equity Research, H.C.
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) will take place at the following scientific conferences:
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago.
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026 Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.
Korro Announces Oversubscribed $85 Million Private Placement
CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced it has entered into a subscription agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $85 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about Tuesday, March 10, 2026, subject to satisfaction of customary closing conditions.
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, three have given a buy recommendation and one has issued
Korro to Present at the TD Cowen 46th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar's presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET.
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE
Korro Bio (NASDAQ: KRRO) used its Analyst Day to outline the rationale and development plans for KRRO-121, an RNA-editing therapeutic candidate the company believes could provide a new approach to controlling elevated blood ammonia in urea cycle disorders (UCD) and hepatic encephalopathy (HE). Management and invited speakers emphasized the clinical burden of hyperammonemia, limitations of current
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Price Targets
Korro Bio price target lowered to $15 from $20 at H.C. Wainwright
$15.00
(was $9.97)
Mitchell Kapoor
·
H.C. Wainwright
Korro Bio (KRRO) PT Raised to $22 at Cantor Fitzgerald on UCD Potential
$22.00
(was $11.50)
Steve Seehouse
·
Cantor Fitzgerald
Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform
$23.00
(was $11.50)
Ryan Deschner
·
Raymond James
Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy
$18.00
(was $11.23)
Raymond James
Korro Bio upgraded to Buy from Neutral at H.C. Wainwright
$20.00
(was $11.69)
H.C. Wainwright
Korro Bio upgraded to Buy from Neutral at Chardan
$15.00
(was $11.69)
Chardan Capital
Korro Bio upgraded to Overweight from Neutral at Piper Sandler
$30.00
(was $11.69)
Yasmeen Rahimi
·
Piper Sandler
William Blair Reiterates Market Perform Rating on Korro Bio Inc. (KRRO), 'early stages of its pipeline with clinical data unlikely until 2027'
$10.00
(was $11.17)
Myles Minter
·
William Blair
Korro Bio upgraded to Outperform from Perform at Oppenheimer
$22.00
(was $10.74)
Oppenheimer
Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald
$21.00
(was $10.74)
Steve Seedhouse
·
Cantor Fitzgerald
Korro Bio initiated with a Buy at Chardan
$25.00
(was $13.46)
Keay Nakae
·
Chardan Capital
Korro Bio Inc. (KRRO) PT Raised to $105 at RBC Capital
$105.00
(was $76.94)
Luca Issi
·
RBC Capital
BMO Capital Reiterates Outperform Rating on Korro Bio Inc. (KRRO)
$120.00
(was $50.05)
Kostas Biliouris
·
BMO Capital
Korro Bio Inc. (KRRO) PT Raised to $115 at H.C. Wainwright, 'KRRO-110 should be well-positioned'
$115.00
(was $88.53)
H.C. Wainwright
Korro Bio Inc. (KRRO) PT Raised to $90 at RBC Capital
$90.00
(was $89.83)
RBC Capital